Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

This study examines the influence of renal dysfunction on stroke risks in two atrial fibrillation (AF) study groups. The ROCKET AF trial was a trial comparing fixed-dose rivaroxaban, a direct factor Xa inhibitor, with adjusted-dose warfarin for prevention of thromboembolic events.

Renal Disease and Stroke Risk in Atrial Fibrillation